Overview

With a fully integrated brand and generics business, the U.S. market is Alvogen’s single largest market. The company has been one of the fastest growing pharma companies in the pharmaceutical industry with a well targeted generics and brand portfolios, as well as commercial and product development infrastructure and pharmaceutical contract services. 

Alvogen is built on the strong foundation of Norwich Pharmaceutical Services, an U.S. company with a 130-year history and an unsurpassed regulatory track record.

79 pipeline ANDA’s
79
28 first-to-file opportunities
28

Products

High value generics

Alvogen product portfolio is focused on complex high value generics and brands, including; niche generics, patches, controlled release and narcotics. The company currently has over 79 ANDA’s in its pipeline and 28 first-to-file opportunities.

US Management

Leadership team

The Alvogen U.S. leadership team has a proven industry track record. Our organizational structure is lean and flexible, driving quick and effective decision making. The U.S. team is led by Lisa Graver.

Meet management

Lines of business

Alvogen business in the US is categorized into two major focus areas; generic pharmaceuticals and sales of third party services, such as contract manufacturing, pilot plant contract development and clinical research.

Third party contract manufacturing and development services are provided by the Company's manufacturing facility in Norwich located in New York State under the Norwich Pharmaceuticals brand.

“Despite an amazing history of growth, this business is poised for even greater success. With fantastic people and our emphasis on a high value difficult to make portfolios, we have the right formula.”  

William Hill
EVP of US Commercial Operations

Connect with customer service

Would you like to learn more about Alvogen, speak with our management or do you have an idea for partnership or future collaboration? We would like to hear from you.

Alvogen USA

10 Bloomfield Avenue 
Pine Brook, NJ 07058
Phone: 973.796.3400
Fax: 973.215.2280